NASDAQ:LQDA

Track all markets on TradingView - Prices are not updated in real time
Liquidia Slips 0.25% as YUTREPIA Sales Surge but Litigation Settlement Drives Large Net Loss

Liquidia (NASDAQ: LQDA) shares slipped about 0.25% after the company reported strong YUTREPIA sales growth and improving adjusted profitability, while a large litigation settlement drove a substantial GAAP net loss.

Third-quarter YUTREPIA net product sales reached $222.7 million, up 31% sequentially and more than fourfold from $51.7 million a year earlier. Patient shipments reached a record monthly level in October, referral-to-start conversion remained above 87%, and the prescriber base expanded to 1,300.

Excluding settlement-related charges, operating momentum remained strong. Liquidia posted its fifth consecutive quarter of higher non-GAAP adjusted EBITDA, reaching $140.5 million.

However, the company recorded a $389.7 million litigation settlement charge, resulting in a quarterly net loss of $236.3 million, or $2.64 per share. The global settlement with United Therapeutics requires net payments of $380.7 million across 2026 and 2027 and also removes the PH-ILD indication from YUTREPIA’s label.

Liquidia ended September with $396.1 million in cash and cash equivalents before settlement payments and continues to advance additional YUTREPIA and L606 programs.

The modest 0.25% decline appears to reflect the financial impact and strategic consequences of the settlement, partly offset by very strong YUTREPIA commercial growth and continued improvement in adjusted profitability.
💬
Author
WS Investor 11-10-26
Liquidia Stock Falls 4.5% Despite Strong YUTREPIA Growth and Rising Profitability

Liquidia Corporation (NASDAQ: LQDA) shares fell 4.5% Wednesday despite reporting another strong quarter for YUTREPIA, with product sales rising sequentially and the company delivering its fourth consecutive quarter of increasing profitability.

The decline contrasts with the company's underlying commercial momentum. With no new financial guidance provided in the release, the negative reaction may reflect high expectations already embedded in the stock, alongside rising operating expenses and investor focus on whether YUTREPIA's rapid launch trajectory can be sustained.

YUTREPIA Sales Rise 31% Sequentially

YUTREPIA generated $170.4 million in Q2 net product sales, up 31% from the first quarter. The year-over-year comparison was even stronger, with product sales increasing from just $6.5 million in Q2 2025, when the commercial launch had only recently begun.

Since its June 2025 launch, Liquidia has received approximately 5,900 unique patient prescriptions and started more than 5,000 patients on treatment through July 31.

Prescription-to-start conversion remained above 85%, while the number of prescribers exceeded 1,100. More than 30% of those physicians have prescribed YUTREPIA to at least five patients, suggesting adoption is broadening beyond initial use.

Management also said the overall inhaled prostacyclin category has expanded almost 40% since YUTREPIA's launch, with the product capturing an increasing share of that growth.

Liquidia Delivers Another Profitable Quarter

Rapid commercialization has transformed Liquidia's financial profile.

The company generated Q2 net income of $74.7 million, or $0.74 per diluted share, compared with a $41.6 million loss a year earlier. Adjusted EBITDA reached $96.3 million.

Cash and cash equivalents increased to $284.2 million at the end of June from $190.7 million at the end of 2025. Cash also increased by $61.4 million sequentially during Q2, demonstrating strong cash generation from the YUTREPIA ramp.

However, investment is rising alongside commercialization. R&D expenses jumped 185% to $17.2 million, primarily reflecting increased spending on L606 and YUTREPIA development. SG&A expenses increased 48% to $57.4 million as Liquidia expanded personnel and commercialization activities.

Pipeline Investment Becomes the Next Focus

Liquidia is now progressing 10 clinical studies involving YUTREPIA and L606 across existing and potential new indications.

The company has begun site activation and enrollment for Re-Spire, the pivotal study of L606. Management sees the program as a potential next-generation inhaled treprostinil therapy that could further improve tolerability and dosing characteristics.

LQDA's 4.5% decline therefore does not appear to reflect deterioration in YUTREPIA's commercial performance. Sales, patient adoption, profitability and cash generation all continued to improve. Instead, the reaction may reflect demanding investor expectations following the product's rapid launch, combined with higher R&D and commercialization spending and the absence of a new forward financial outlook to provide an additional catalyst.
💬
Author
WS Investor 08-12-26
Liquidia Corporation received a $50 million payment from Healthcare Royalty (HCRx) after initiating commercial sales of YUTREPIA™, its inhaled therapy for pulmonary hypertension. The funding follows a court ruling denying United Therapeutics' injunction against Liquidia. To date, Liquidia has secured $175 million out of a potential $200 million through its agreement with HCRx. The funds will accelerate YUTREPIA’s launch, support clinical trials, and expand manufacturing. An additional $25 million may be accessed if net sales exceed $100 million by mid-2026. Liquidia believes this funding will help reach profitability without needing more capital.
💬
M
ME NEWS 06-24-25